People News
Dr. Jim Esinhart
Elligo Health Research has welcomed Brandon Cormier as chief commercial officer, Jody Casey as the company’s new vice president of healthcare partnerships, and Faith Holmes as medical director.
Ergomed plc has announced its intention to appoint Dr. Jim Esinhart as a non-executive director of the company.
Antidote announces that Kathy Freeman has joined their executive management team as VP of business development.
The Society for Clinical Research Sites announced that Jennifer Burgess, executive director of communications and engagement for TransCelerate BioPharma Inc., has joined the organization’s Leadership Council.
Business News
QPS hosts 28 Taiwanese delegates at headquarters
QPS announced its plans for continued growth in Asia after hosting a 28-member delegation from Taiwan at its headquarters in Delaware.
Recognition
PPD-SNBL has been named a top-five growth business and desirable employer by Randstad Japan.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.